Kura Oncology

Troy Edward Wilson purchased about 100,000 Kura Oncology shares on Aug. 24, 2026 at a weighted average price of $12.39, a $1.2 million transaction that raises his total beneficial ownership to roughly 1.2 million shares. The purchase increases his stake by about 9% and includes holdings via the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The trade occurred with Kura Oncology at a $1.1 billion market cap; the company reported TTM revenue of $77.2 million and a net loss of $296.8 million. The article frames the insider buy as a potentially bullish signal for the stock. » Más en finance.yahoo.com

Kura Oncology shares jumped sharply in premarket trading after CEO Troy Edward Wilson bought 100,000 common shares on August 24, 2026 through a trust at a weighted average price of $12.39 — his second large purchase within a week, raising his economic ownership to 479,194 shares (plus 300,000 shares in a foundation). Citizens affirmed a "Market Outperform" rating with a $24.00 price target, and Jefferies also reiterated a buy recommendation. Kura also reported an adjusted Q2 loss of $0.77 per share (better than the $0.88 estimate) and revenue of $20.87 million (above expectations), boosting the positive market reaction; the stock climbed above its 52-week high of $12.90. » Más en de.investing.com

Kura Oncology’s stock rose to a 52‑week high of 12.49 USD and is currently trading at 12.64 USD, implying a market capitalization of around 1 billion USD. For the second quarter of 2026 the company reported an adjusted loss of 0.77 USD per share on revenue of 20.87 million USD, beating Wall Street estimates. The stock is up about 56.9% year‑to‑date; seven analysts raised their estimates, while an analysis by InvestingPro points to possible overvaluation. CEO Troy Edward Wilson made an insider purchase of 100,000 shares at a weighted average price of 11.12 USD per share, executed in multiple trades. » Más en de.investing.com